Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	36.79	26.63
Cash & Short-Term Investments	36.79	26.63
Cash Growth	38.12%	-
Accounts Receivable	23.22	12.88
Inventory	1.57	1.06
Other Current Assets	5.47	3.55
Total Current Assets	67.04	44.12
Other Long-Term Assets	3.51	0.82
Total Assets	70.55	44.95
Accounts Payable	4.64	3.24
Accrued Expenses	5.64	3.43
Current Portion of Leases	-	0
Unearned Revenue	0.25	0.25
Total Current Liabilities	10.52	6.92
Long-Term Debt	-	19.34
Other Long-Term Liabilities	24.56	24.56
Total Long-Term Liabilities	24.56	43.9
Total Liabilities	35.08	50.82
Common Stock	189.91	145.61
Additional Paid-in Capital	73.75	66.96
Accumulated Other Comprehensive Income	1.24	1.24
Retained Earnings	-229.42	-219.68
Shareholders' Equity	35.47	-5.87
Total Liabilities & Equity	70.55	44.95
Total Debt	0	19.34
Net Cash (Debt)	36.79	7.29
Net Cash Growth	404.36%	-
Net Cash Per Share	1.29	0.27
Book Value	35.47	-5.87
Book Value Per Share	1.24	-0.22
Tangible Book Value	35.47	-5.87
Tangible Book Value Per Share	1.24	-0.22

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q